Imagine buying an expensive bottle of whisky to celebrate a new job, taking assorted drinks home for your family during the Christmas season, or purchasing medicine from a shop because you trust the name printed on its packaging. Now imagine discovering that the drink may have been tampered with or that the medicine you depend on contains the wrong ingredients.
For many Nigerians, the danger of counterfeit products is no longer simply about losing money to dishonest sellers. It raises serious questions about public health, the effectiveness of medical treatment and the safety of everyday goods consumed in homes, markets, workplaces and hospitals.
Recent enforcement operations by the National Agency for Food and Drug Administration and Control (NAFDAC) in Lagos and Aba, Abia State, have brought these concerns into sharper focus. The agency reportedly uncovered a suspected illegal beverage operation in Lagos and seized counterfeit packaging materials valued at more than ₦200 million in Aba.
The discoveries have renewed concerns about the circulation of suspected fake drinks, falsified medicines, adulterated food products and other potentially unsafe goods in Nigeria. Health professionals warn that when consumers cannot establish the authenticity of products they buy, the consequences may extend from financial losses to serious illness and, in some circumstances, death.
One of the reported discoveries occurred at Zamfara Plaza, BBA Trade Fair Complex, along the Badagry Expressway in Ojo, Lagos State.
NAFDAC operatives reportedly uncovered a suspected facility operating from a two-storey building where alcoholic and energy drinks were allegedly being produced or repackaged illegally. The operation followed intelligence gathering and surveillance targeting suspected counterfeiters within the Trade Fair International Market.
During the raid, two suspects identified as Chibuzor Okafor and William John were arrested. Officials reportedly recovered drums, filters, packaging materials, a heating device and other equipment suspected to have been used in the operation.
According to the agency, some of the suspects were caught in the act.
Speaking during the operation, Kunle Ojo, an assistant director in NAFDAC’s Investigation and Enforcement Directorate, expressed concern about the scale of the discovery.
What we have discovered today is a lot, and it’s mind-boggling. We are here to protect the lives of many Nigerians, he said.
One of the most troubling aspects of the raid emerged from the explanation reportedly given by Okafor, who identified himself as a drinks dealer in the market.
He told Saturday Vanguard that he changed the bottles of drinks, explaining that the contents of one bottle were transferred into another because the original drink was allegedly damaged.
His account raises questions about the origin, composition and safety of the beverages involved, as well as whether consumers purchasing such products could determine if the contents were genuine.
A bottle may carry a familiar brand name, an attractive label and packaging that resembles a product consumers have trusted for years. However, those features alone cannot guarantee authenticity when a beverage has been tampered with or repackaged outside legitimate quality-control procedures.
For someone purchasing wine for a family gathering, whisky for a celebration or an energy drink to stay alert at work, the transaction may appear ordinary. The danger is that the consumer may have no obvious reason to suspect that the product has passed through an unauthorised operation.
The Lagos operation was not the only reported discovery. In Aba, Abia State, NAFDAC operatives raided shops at Old Court Road Market following what the agency described as credible intelligence about counterfeiting and the production of packaging materials for branded spirits, wines and other regulated products.
The operation reportedly uncovered large quantities of labels, corks and outer packaging materials bearing the names of established brands.
Among the brands identified were Jameson, Glenfiddich, Four Cousins, Lord’s Dry Gin and Imperial Blue. Materials bearing the names of Chelsea, Squadron and Seaman’s Aromatic Schnapps were also reportedly recovered. The agency further said it found packaging materials associated with Goya oil.
NAFDAC estimated the value of the counterfeit packaging materials recovered from five shops at more than ₦200 million.
The concern is that such materials, when used fraudulently, can help make unauthorised products appear to be genuine goods manufactured by established companies. Counterfeiters may exploit familiar labels, bottle closures and outer packaging to mislead consumers who rely on brand recognition when making purchasing decisions.
The operation reportedly encountered resistance. According to NAFDAC, traders confronted operatives with threats and intimidation, while some allegedly pursued the vehicle transporting the recovered materials and threatened people assisting with their evacuation.
The owners of the shops visited reportedly fled, and the affected premises were placed on hold pending further action.
The discoveries in Lagos and Aba illustrate different aspects of the suspected counterfeit trade. While the Lagos operation involved a suspected facility for handling or repackaging drinks, the Aba raid exposed packaging materials that could potentially be used to make unauthorised products resemble established brands.
The cases underscore why tackling counterfeiting requires more than seizing finished goods. Investigators must also identify the people, materials, distribution networks and supply chains that enable the trade.
For consumers, the danger of counterfeit drinks goes beyond whether a product is genuine. The more important questions concern what the beverage contains, how it was produced, whether it has been contaminated and whether it meets the safety standards required of regulated products.
Not every counterfeit drink poses the same risk. A beverage carrying fraudulent branding may contain a genuine drink that has been unlawfully repackaged. Another product may have been diluted, adulterated or manufactured with unsafe ingredients.
Without appropriate testing, it is not possible to determine the exact composition or level of danger associated with every suspected counterfeit product recovered during enforcement operations.
One particularly serious risk is methanol contamination in alcoholic beverages. Methanol is toxic, and consuming sufficient quantities can cause severe metabolic disturbances, visual impairment, permanent blindness and death. Other contaminants and unsafe production practices may also cause harm, depending on the substance involved and the extent of exposure.
However, it would be inaccurate to claim that every counterfeit bottle of wine or whisky contains methanol or necessarily causes kidney or liver damage.
The concern is that consumers may be unable to establish the contents or safety of a product that has been tampered with outside authorised production and quality-control systems.
A bottle may look genuine while its contents tell a different story. This uncertainty makes suspected counterfeit beverages a serious public health concern.
The problem is not limited to alcoholic drinks. Medicines, cosmetics, packaged water, food products and other regulated goods can also be adulterated, contaminated, improperly manufactured, falsely labelled or sold without the required registration.
Some products imitate the packaging of established brands, making it difficult for ordinary consumers to distinguish genuine goods from fraudulent copies.
The danger is particularly serious when medicines are involved.
A person suffering from malaria may take what appears to be the correct medication but fail to recover. Someone living with hypertension may continue taking tablets without achieving adequate blood pressure control. A pregnant woman may unknowingly consume a falsified supplement, while a family already struggling with medical bills may spend its savings on treatment that does not work as expected.
In such circumstances, consumers may have purchased a product in good faith, followed the instructions and trusted the systems designed to protect them. Yet the product itself may be part of the problem.
Falsified or substandard medicines can undermine treatment, expose patients to harmful substances and delay effective medical care. Depending on the product and circumstances, the consequences can include serious injury or death.
The wider economic effects can also be substantial. Families may face repeated hospital visits, additional medical expenses, lost working hours and uncertainty about whether the medicines they purchase can be trusted.
Consider a patient identified in the source account as Doris Ibe, who experiences persistent malaria symptoms despite receiving treatment.
As the illness continues, she returns for consultations and spends more money on tests, transportation and medication. She and her family may begin to question whether the diagnosis was wrong, the illness has become more severe or the treatment is no longer effective.
One possibility they may need to consider, alongside other medical explanations, is the quality of the medicine.
Treatment failure can occur for several reasons, including an incorrect diagnosis, inadequate dosage, failure to follow the prescribed regimen, drug resistance or complications associated with the illness. It cannot automatically be attributed to counterfeit medicine.
However, when a medicine is falsified or contains too little of the required active ingredient, the wrong ingredients or harmful contaminants, even a correctly prescribed treatment may fail to deliver the expected benefit.
The danger is that a patient’s condition may worsen while the underlying problem remains unidentified.
People living with chronic conditions such as hypertension and diabetes can be especially vulnerable because they often depend on regular medication to control their illnesses. If a product does not contain the expected active ingredient, a patient may believe the condition is being managed while remaining exposed to potentially serious complications.
A counterfeit or contaminated product may also introduce an additional risk through toxicity.
The result can be a cycle of worsening symptoms, repeated hospital visits, rising medical expenses and growing frustration. Patients may lose confidence in healthcare workers, abandon prescribed treatment or turn to unverified alternatives, potentially exposing themselves to further harm.
Nevertheless, persistent symptoms require proper medical assessment because treatment failure can have causes unrelated to product quality.
Alleged Herbal Remedy Case Raises Questions About Product Safety
Concerns about unsafe products also extend to herbal remedies and products advertised through seemingly legitimate channels.
A case reported in Ogun State involved a young woman who allegedly purchased an advertised herbal product after hearing about it on a radio programme in Abeokuta. She reportedly sought the product to treat suspected fibroids.
According to the account, she inserted the substance as directed but subsequently experienced severe pain and a sensation of internal blockage. Medical experts reportedly discovered that the substance was caustic soda, a highly corrosive chemical.
The allegation has not been independently established in the material provided. If confirmed as reported, however, the case would illustrate the potentially devastating consequences of using products whose ingredients and safety have not been properly verified.
A woman seeking relief from a reproductive health concern could instead suffer a serious chemical injury.
The account raises questions about the marketing of purported remedies, the verification of ingredients and the responsibility of people who advertise, distribute or sell substances intended for human use.
It also highlights the vulnerability of consumers seeking quick solutions to distressing health problems. When conventional healthcare is expensive, access to specialists is limited or symptoms cause anxiety, a persuasive advertisement may appear to offer hope. That hope can be exploited when product claims are not supported by reliable evidence.
Consumers should therefore be cautious about remedies advertised as miracle cures, particularly products promoted for serious medical conditions without clear evidence of safety and effectiveness.
The President of the Health Care Providers Association of Nigeria (HCPAN), Dr Austin Aipoh, described substandard and falsified medicines as a major challenge for the country’s healthcare system.
Speaking to Saturday Vanguard, Aipoh identified treatment failure as one of the immediate consequences of poor-quality or fake medicines.
He explained that patients who fail to improve may become frustrated and lose confidence in their doctors, healthcare facilities and the wider Nigerian health sector.
“When treatment fails, the patient may lose confidence in the doctor, the facility and the Nigerian health sector,” he said.
According to Aipoh, repeated illness and unsuccessful treatment can drain household resources. Families that should be spending money on food, children’s education and other essential needs may instead find themselves paying for repeated consultations, diagnostic tests and new prescriptions.
He also warned that ineffective medicines can allow illnesses to progress before patients receive effective treatment.
In malaria cases, delays in effective treatment can increase the risk of severe disease. Inadequate control of hypertension can raise the risk of stroke and other cardiovascular complications, while poorly controlled diabetes can contribute to damage affecting several organs.
Aipoh stressed that these outcomes should not automatically be blamed on counterfeit products in every case. His concern was that falsified or substandard medicines can prevent patients from receiving the treatment needed to control their conditions.
He also raised concerns about toxic reactions, explaining that the effects depend on the ingredients involved and the extent of exposure. Some contaminants may cause acute kidney injury or damage other organs, while the effects of other harmful substances may emerge over time.
Aipoh recalled a past incident involving a toxic teething product marketed for children, which he associated with kidney damage and deaths. He said such incidents demonstrate why the quality and composition of medicines and other healthcare products must not be compromised.
He called for stronger regulatory oversight, improved reporting systems and greater public awareness. Healthcare professionals, he argued, should have effective channels for reporting suspected substandard medicines when patients do not respond to treatment as expected.
Such reports could help regulators identify problematic products or batches, investigate supply chains and take action before more people are exposed.
Aipoh also advocated stronger domestic pharmaceutical manufacturing, arguing that improved local production and quality control could strengthen accountability. He acknowledged, however, that local manufacturing alone would not eliminate counterfeiting.
Manufacturers, importers, distributors, wholesalers and retailers must all comply with quality standards, while regulators must verify that products meet the required specifications. He also called for stronger oversight of medicine distribution and proposed establishing a special court to handle cases involving counterfeit products.
Dr Casmier Ifeanyi, a public health expert and National President of the Association of Medical Laboratory Scientists of Nigeria, also warned about the far-reaching public health consequences of counterfeit medicines, food and beverages.
“The public health implication is incalculable,” Ifeanyi said, warning that the consumption of fake medicines, food products and beverages can contribute to serious health complications and, in some cases, death.
He highlighted the risks for patients who depend on medicines to manage chronic illnesses. A person with hypertension taking falsified medication may fail to achieve adequate blood pressure control and face an increased risk of cardiovascular complications, including stroke.
The same concern applies to patients receiving treatment for malaria and other illnesses. An ineffective antimalarial may fail to provide the intended benefit, allowing the infection to persist or worsen. The consequences depend on the patient’s condition, the disease and the actual composition of the product.
Ifeanyi also expressed concern about pregnant women who depend on prescribed medicines and supplements. A falsified product may fail to provide the intended nutritional or therapeutic benefit, while harmful contaminants could create additional risks depending on the substance and the level of exposure.
He warned that the circulation of counterfeit products can also undermine public confidence in healthcare professionals. When treatment fails, patients may wrongly assume that their doctors lack the necessary expertise, even when the underlying problem is an ineffective or unsafe product.
Ifeanyi questioned the effectiveness of market surveillance and post-registration monitoring by NAFDAC. He argued that registering a product should not mark the end of regulatory responsibility, because medicines, food and beverages must continue to be monitored after they enter the market.
“The agency should concern itself with the quality and integrity of products that receive their listing and numbering,” he said.
He also questioned why ordinary consumers sometimes appear to play a prominent role in identifying suspected counterfeit goods, arguing that the agency should strengthen its intelligence gathering, surveillance and enforcement systems.
NAFDAC, however, has reported carrying out raids, seizures, arrests, investigations, closures of premises and destruction of unsafe products. The central issue is whether these activities are sufficiently preventive and consistent to stop dangerous goods from reaching consumers.
Ifeanyi called for stronger post-market surveillance, improved public education and clearer guidance to help consumers identify suspected adulteration and verify product authenticity. He also advised healthcare facilities to obtain medicines through reputable and traceable supply channels.
NAFDAC’s reported enforcement figures provide an indication of the scale of the challenge facing regulators.
Data recently released by the agency’s Directorate of Investigation and Enforcement showed that, between January and August 2026, NAFDAC recorded 5,542 enforcement activities, conducted 213 raids, documented 821 product seizure entries and closed or sealed 179 premises.
The agency also reported 52 arrests, 474 newly reported cases, 295 concluded cases and 22 product destruction exercises during the eight-month period.
The value of unsafe products destroyed was reported at approximately ₦22.73 billion. The products covered a broad range of regulated categories, including medicines, food, beverages, cosmetics, chemicals, packaged water and medical devices.
Monthly figures showed considerable enforcement activity throughout the period. NAFDAC recorded 232 activities in January, rising to 423 in February and 673 in April. The number reached 1,076 in May and 1,089 in July, the highest monthly figure reported for the period, before standing at 941 in August.
Cosmetics accounted for 401 seizure entries, followed by drinks with 215, drugs with 112, food with 69 and chemicals with 22.
The figures show that the challenge extends beyond medicines to products Nigerians routinely consume, apply to their bodies or use in their homes.
Enforcement work also involves intelligence gathering, investigations, product assessments, administrative sanctions and referrals for possible prosecution.
Destroying unsafe products is important because it prevents the recovered goods from being sold or consumed. However, the number and value of products destroyed do not, by themselves, establish how many consumers have been protected or whether the overall prevalence of counterfeiting is declining.
Assessing progress requires sustained surveillance, reliable market data and evidence that compliance is improving while fewer dangerous products reach consumers.
The growth of online commerce has introduced another challenge for regulators.
Nigerians increasingly buy medicines, cosmetics and other healthcare products through social media pages, online marketplaces and sellers operating through personal accounts. Although these platforms offer convenience, they can make it harder for buyers to establish a seller’s identity, verify the origin of a product or confirm that the item delivered is the one advertised.
NAFDAC Director-General, Professor Mojisola Adeyeye, has acknowledged the challenge posed by online marketing.
According to remarks attributed to her at a press briefing in Lagos, the agency deployed corps members and interns to monitor product sales on platforms including Instagram, Facebook, Jiji, Jumia and Konga. Information gathered through the monitoring exercise is submitted for review and may lead to investigations, arrests or enforcement action.
Adeyeye said the online sale of unregistered or counterfeit eye drops and other healthcare products had become a growing concern. She also said the agency had identified and sanctioned unregistered products, shut down some businesses and handed suspects over for further investigation and possible prosecution.
According to her, penalties imposed on some businesses ranged from ₦200,000 for micro businesses to ₦5 million for larger businesses.
She also said NAFDAC was working with online marketplaces on compliance measures, including the Scan2Verify system and the Green Book, which helps consumers check registered products. Buyers, particularly those purchasing eye-care products and other healthcare items, were urged to verify registration through official channels.
The agency has also reported cases in which information gathered online led investigators to physical premises, resulting in arrests and the discovery of other suspected illegal activities.
However, online monitoring remains difficult. Sellers may operate multiple accounts, change identities or move between platforms, while informal distribution networks can complicate efforts to identify and hold the responsible parties accountable.
An attractive advertisement, a familiar brand image or a seller’s assurance should therefore not be treated as sufficient proof that a healthcare product is genuine or safe.
Health professionals argue that enforcement must be accompanied by reforms that make counterfeiting more difficult and improve the chances of identifying unsafe products before they cause harm.
Aipoh called for stronger regulatory powers, more effective prosecution and specialised mechanisms for handling cases involving fake medicines and other dangerous products. He also urged healthcare professionals to report suspected treatment failures and products of questionable quality through a coordinated surveillance system.
Such reporting could help regulators identify patterns, investigate products and act quickly when evidence points to a safety or quality problem.
Ifeanyi emphasised the need for routine post-market surveillance. A product that meets regulatory requirements at one stage should not automatically be assumed to remain compliant indefinitely, particularly where there is a risk of falsification, improper storage, contamination or diversion along the supply chain.
Both experts highlighted the importance of public education. Consumers need to know how to verify regulated products, where to report suspected counterfeits and why medicines should be purchased through legitimate, traceable channels.
Healthcare professionals and pharmacists also have a role in explaining the dangers of self-medication and ensuring that persistent treatment failure receives proper investigation. A poor response to treatment should not automatically be assumed to indicate drug resistance, a more severe illness or a counterfeit product without appropriate assessment.
Aipoh further called for stronger laboratory capacity, better intelligence sharing, transparent enforcement reporting and cooperation among regulatory agencies. Manufacturers and distributors, meanwhile, must ensure that products are properly manufactured, stored, transported and labelled.
Online marketplaces also have a responsibility to take reasonable steps to prevent prohibited and unsafe products from being sold through their platforms.
Ultimately, enforcement should be measured not only by the quantity of goods seized but also by whether fewer dangerous products reach consumers, offenders are held accountable and patients can trust the medicines on which they depend.
For ordinary consumers, the problem may begin with a routine purchase: a bottle of wine, a packet of tablets, a container of palm oil or a cosmetic advertised online. Although consumers cannot independently detect every form of counterfeiting, there are practical precautions they can take.
Medicines should be purchased from licensed and reputable pharmacies or healthcare providers. Consumers should be cautious about products advertised with exaggerated claims, particularly those promising miraculous cures for serious conditions.
Packaging that appears altered, incomplete or suspicious should prompt further checks. Buyers should examine product labels and registration details and, where possible, verify them through NAFDAC’s official channels. However, a registration number alone is not conclusive proof of authenticity because counterfeiters may copy details from genuine products.
Consumers should also be cautious when buying regulated products from unknown online sellers or vendors who cannot provide reliable information about a product’s source.
Anyone who suspects that a medicine is ineffective, contaminated or associated with an unexpected reaction should seek medical advice and report the concern through appropriate healthcare and regulatory channels.
People taking prescribed medicines, particularly for chronic conditions such as hypertension and diabetes, should not stop or change their treatment without professional guidance. Persistent symptoms require proper medical assessment because there may be several possible explanations for treatment failure.
When it comes to alcoholic beverages and other packaged products, a familiar label or attractive bottle should not be taken as a guarantee of authenticity. Where a product appears suspicious, consumers should avoid using it and seek guidance from appropriate authorities.
The reported destruction of ₦22.73 billion worth of unsafe products between January and August 2026 is a significant enforcement figure. It also highlights the scale of the challenge regulators say they are confronting.
The Lagos and Aba operations illustrate how suspected counterfeiting may involve both the contents of bottles and the labels, corks and packaging that can make unauthorised goods appear genuine.
But the ultimate measure of success is not simply the number of labels confiscated, buildings raided or products destroyed. It is whether the people behind the operations are identified, the supply chains that sustain the trade are disrupted and consumers are protected from unsafe goods.
For NAFDAC, the task is to sustain enforcement while strengthening systems that prevent dangerous products from entering the market. For healthcare professionals, it is to remain alert to suspected treatment failures, report concerns and help patients access reliable medicines.
Manufacturers, distributors and retailers must recognise that product integrity is not merely a commercial obligation but a matter of public safety. Government must also ensure that regulatory institutions have the resources, intelligence and accountability mechanisms needed to carry out their responsibilities effectively.
The most troubling feature of counterfeit products is that their victims may never know what went wrong. A patient may blame a doctor, a family may exhaust its savings on repeated treatment, or a consumer may suffer complications without realising that the product they trusted was unsafe.
The fight against fake drugs, counterfeit drinks and adulterated food must therefore extend beyond market raids and destruction exercises. It must reach every stage of the supply chain, from manufacturing and importation to distribution, advertising and retail sales.
For Nigerians, the stakes are clear: the safety of the medicines they take, the food they eat and the drinks they serve their families depends on effective regulation, responsible businesses and informed consumer choices.
Visit www.rapidospace.com for more news and public-interest reports.
